leisure time -WSS

leisure time

author：leisure time 2025-10-01 05:38:38 - browse：4385

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Roche’s Alnylam deal shows drug firms interested in heart drugs

knowledge

entertainment

WSS

A new nitrogen execution bill also undermines medical licensing

Why patients can’t get everything they want on drug pricing

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

6 phony surgeries that take placebo to the extreme

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

NIH study of ME/CFS points to clear biological hallmarks

knowledge

leisure time

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Truvian presents data for its desktop blood

The high cost of giving birth even with insurance

UHS says company favors patients whose insurance pays more

After affirmative action ruling, medical educators look to 'holistic review'

New Alzheimer's drugs heat up race for early detection blood tests

After affirmative action ruling, medical educators look to 'holistic review'

Alabama frozen embryo ruling has major implications for IVF clinics

Cancer drug shortages should be causing more outrage

Senate panel puts off hardest PBM reforms for another day

hotspot

Alabama IVF ruling threatens families facing fatal genetic disease

Alabama IVF ruling threatens families facing fatal genetic disease

Democrats decry new health bill for going easy on private equity

Device maker Teleflex to acquire urology company for $600M

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Alabama hospital puts IVF treatments on hold

focus

knowledge

entertainment

explore